CYP2C8 along with CYP2B6, CYP3A4, and CYP3A5 metabolize drugs used in artemisinin-based combination therapy for malaria, and alleles such as CYP2C8*2, CYP2C8*3, CYP2B6*6, CYP3A4*1B, and CYP3A5*3 may affect patient response to this treatment [21]. The gene discussed is CYP2C8; the disease is malaria.